All In Biotech

Drug Trial Radar · NCT04586010

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

A Phase III Multicenter Randomized, Double-blind, Double-dummy, Parallel-group Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Adult Patients With Relapsing Multiple Sclerosis

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 746 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

746

Actual

Start

Mar 17, 2021

Primary completion

Jan 27, 2026

Study completion Nov 30, 2027

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Oct 14, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study to evaluate the efficacy and safety of fenebrutinib on disability progression and relapse rate in adult participants with RMS. Eligible participants will be randomized in a 1:1 ratio to receive either fenebrutinib or teriflunomide. At the end of the double-blind treatment (DBT) phase (after disclosure of the DBT results), the Sponsor will determine whether or not to initiate the open-label extension (OLE) phase of the study.

Conditions

  • Relapsing Multiple Sclerosis

Interventions

  • FenebrutinibDrug

    Participants will receive fenebrutinib.

  • TeriflunomideDrug

    Participants will receive teriflunomide.

  • PlaceboDrug

    Participants will receive teriflunomide-matching placebo or fenebrutinib-matching placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Relapse Rate (ARR)Time frame: Minimum of 96 weeks

Locations

158 sites in 23 countries. Site status is shown where the registry gives one.

  • University of Alabama Birmingham

    Birmingham, Alabama

  • Alabama Neurology Associates

    Homewood, Alabama

  • Center for Neurology and Spine - Phoenix - Hunt - PPDS

    Phoenix, Arizona

  • Profound Research, LLC

    Carlsbad, California

  • University of California Irvine

    Irvine, California

  • Quantum Clinical Research, Inc

    Pasadena, California

  • University of Colorado Denver

    Aurora, Colorado

  • Mountain View Clinical Research

    Denver, Colorado

  • Advanced Neurology of Colorado, LLC

    Fort Collins, Colorado

  • Neurology Associates, PA; Research Department

    Maitland, Florida

  • NorthShore University HealthSystem

    Highland Park, Illinois

  • Fort Wayne Neurological Center

    Fort Wayne, Indiana

  • The NeuroMedical Center

    Baton Rouge, Louisiana

  • Ochsner LSU Health

    Shreveport, Louisiana

  • Johns Hopkins University School Of Medicine; Outpatient Center

    Baltimore, Maryland

  • University of Massachusetts Medical School

    Worcester, Massachusetts

  • Henry Ford Health System

    Detroit, Michigan

  • Washington University School of Medicine

    St Louis, Missouri

  • Holy Name Hospital; Institute For Clinical Research

    Teaneck, New Jersey

  • University of New Mexico; MS Specialty Clinic

    Albuquerque, New Mexico

  • Miami Valley Hospital South; Dayton Physician's Office

    Centerville, Ohio

  • OhioHealth

    Columbus, Ohio

  • The Boster Center for Multiple Sclerosis a Singlepoint Healthcare Company

    Columbus, Ohio

  • Oklahoma Medical Research Foundation; MS Center of Excellence

    Oklahoma City, Oklahoma

  • St. Luke's University Health network

    Bethlehem, Pennsylvania

  • Premier Neurology

    Greenville, South Carolina

  • New Orleans Center for Clinical Research

    Knoxville, Tennessee

  • North Texas Institute of Neurology and Headache NextStage Clinical Research Clinic

    Plano, Texas

  • Texas Institute for Neurological Disorders

    Sherman, Texas

  • Multiple Sclerosis Center of Greater Washington

    Vienna, Virginia

  • Evergreen MS Center

    Kirkland, Washington

  • Wheaton Franciscan Healthcare - St. Francis Outpatient Center; Center for Neurological Disorders

    Milwaukee, Wisconsin

  • Neurologia Infantil Buenos Aires (NIBA)

    Buenos Aires, Argentina

  • IME - Instituto Médico Especializado

    Buenos Aires, Argentina

  • Centro de Especialidades Neurológicas y Rehabilitación - CENyR

    Buenos Aires, Argentina

  • CIER

    C. A. B. A., Argentina

  • Diagnostico Medico Oroño

    Rosario, Argentina

  • Cer San Juan

    San Juan, Argentina

  • Centro de Investigaciones Médicas Tucuman

    San Miguel de Tucumán, Argentina

  • Peking University First Hospital

    Beijing, China

Showing 40 of 158 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.